Celgene (CELG): Refusal to File for ozanimod Drives PT To $101 - BofA
Tweet Send to a Friend
BofA/Merrill Lynch analyst, reiterated his Neutral rating on shares of Celgene (NASDAQ: CELG) and cut his PT to $101.after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
